Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States
There was no increased risk of 20 pre-specified AESIs following receipt of the BNT162b2 XBB COVID-19 vaccine among US commercially insured individuals aged ≥6 months. Findings are consistent with the current evidence on the safety of BNT162b2 COVID-19 vaccines. Public registration: EUPAS108135.
Authors
- Jenny W. Sun (ORCID: https://orcid.org/0000-0001-5082-1251)
- Florence T. Wang (ORCID: https://orcid.org/0000-0001-8776-9434)
- Susan Mather
- Eric J. Kim (ORCID: https://orcid.org/0000-0001-8032-2090)
- Nicola Charpentier
- Kofi Asomaning
- K. Nespithal
- Laura E. Dodge (ORCID: https://orcid.org/0000-0002-4024-2034)
- Li Zhou (ORCID: https://orcid.org/0000-0002-6736-0057)
- Henry Goebe
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- New England College of Optometry (US)
- Optum (United States) (US)
- BioNTech (Germany) (DE)
Publication Details
- Journal
- Vaccine
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126629
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- Pfizer